7G BioVentures
Venture capitalBurlingame · 5 people tracked
Find your way into 7G BioVentures
6,391 people in our graph share verified history with the 7G BioVentures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
7G BioVentures targets first-in-class life science innovations, backing scientists, clinicians, and entrepreneurs who translate breakthrough discoveries into life-saving products. The fund is led by partners with decades of life science investment experience and established track records, and it focuses its investment activity on the U.S., Canada, and Europe.
Source: firm website, verified Sep 1, 2026.
Team · 5 people
from the firm's website & public directories
What they invest in
from 13 of 20 portfolio companiesBiotech ×11Healthtech ×8Medical Devices ×7Deep Tech ×4Digital Health ×2
HQs:United States×7Switzerland×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 12019 · 13 dated
Perseo Pharma is a biotech spin-off from the University of Applied Sciences in Basel, Switzerland, developing enzyme immobilization and bioconjugation technologies for therapeutic applications.
BiotechDeep TechDigital HealthMedical DevicesBasel, CH
Dr. Yves Dudal(CEO)Prof. Dr. Patrick Shahgaldian(CSO)
Tucson, AZ and Jupiter, FL-based biotech company offering an immune-focused biologic platform for serious inflammatory and fibrotic disorders.
Aqualung Therapeutics is an early-stage therapeutics company developing a drug discovery platform and pipeline focused on advancing human health.
BiotechHealthtechMedical DevicesTucson, US
Joe G.N. Garcia(Executive Officer, Director)Joe G.N. "Skip" Garcia(Founder & Chief Executive Officer)Shawntela Martinez(Chief Financial Officer (Fractional))Augustine Choi(Chief Medical Officer (Fractional))Stan Miele(President)
Clinical-stage biopharmaceutical company developing best-in-class aryl hydrocarbon receptor agonists.
BiotechEncino, US
Matthew Davidson(Executive Officer, Director)
BoardDennis Brown(Director)
Co-investorsTarnagulla Ventures
BBy manufactures a device that converts breast milk into shelf-stable powder while preserving its immunological properties, serving neonatal intensive care units seeking to reduce preparation time and milk waste.
HealthtechMedical DevicesNew York City, US
Co-investorsY Combinator
BBy develops a condensed breast milk product and process that preserves bioactive immunological properties for hospital distribution.
BiotechHealthtechMedical DevicesChicago, US
BoardDr. Langer
Co-investorsBeresford Ventures
Software helping clinicians consistently deliver best-practice clinical care.
Developing a best-in-class minimally-invasive treatment for ectatic corneal disease to enable early intervention for patients globally.
Epion Therapeutics develops a minimally-invasive cross-linking treatment system called EpiSmart for keratoconus, a corneal disease, designed to preserve vision without disrupting the corneal epithelium.
BiotechDeep TechHealthtechMedical Devices
Michael D. Webb(President & CEO, Board Member)Edward Parsons(Chief Operating Officer)inMichael W. Belin(Chief Medical Officer)
Co-investorsNew World Angels
A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.
Biotech
Co-investorsCerity Partners VenturesHikma VenturesSanofi Ventures
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investorsSanofi VenturesJDRF T1D Fund
Clinical-stage biotechnology company advancing allogeneic CAR-T cell therapies for autoimmune disorders and cancers.
A clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases, targeting off-the-shelf and scalable treatments to improve patient access.
BiotechHealthtechMedical Devices
Lu Han(Chief Executive Officer)Jiangtao Ren(Chief Scientific Officer)Yajin Ni(Chief Technology Officer)
Co-investorsDecheng Capital
Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology.
BiotechHealthtechSeattle, US
Mark Esposito(CSO, Co-Founder and Board Member)inYibin Kang(Chair, Scientific Advisory Board and Co-Founder)Kendall Mohler(Executive Officer, Director)Thong Q. Le(President and CEO, Board Member)Ian Howes(Chief Financial Officer)Merika Koday(COO and Board Member)in
Co-investorsFoundation Venture Capital Group, LLC
Mesentech develops prostaglandin prodrugs aimed at musculoskeletal regeneration.
BiotechHealthtechVancouver
David Hyman(Executive Officer)Robert Norman Young(Executive Officer, Director)Jay Mohr(Director)David Dvorak(Director)Jonathan Polak(Executive Officer, Director, Promoter)
BoardSamuel Wu(Director)
Co-investorsBeresford VenturesWUTIF Capital
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity.
BiotechDeep TechHealthtechPrinceton, US
Robert K. Prud'homme, PhD(Director)Bob Prud'homme(Leadership (PhD))Rob Pagels(Leadership (PhD))Chet Markwalter(Leadership (PhD))inShahram Hejazi, PhD(Executive Officer, Director)inShahram Hejazi(Leadership (PhD))in
Co-investorsAnzu PartnersHatch BioFund
Innovating enzyme therapeutics for the treatment of digestive and orphan diseases.
Improving diabetes management by enhancing patient adherence to glucose monitoring.
Persperion Diagnostics develops touch-based sweat sensing technology for diagnostic measurement.
Deep TechDigital HealthMedical Devices
Co-investorsCornucopian Capital ManagementFoothill VenturesSamsung Next
Portfolio news
latest coverage across their companiesAzora Therapeutics · stocktitan.net · Aug 11, 2026
Optimeos · mychesco.com · Jul 6, 2026
Frequently asked questions
- How many investments has 7G BioVentures made?
- 7G BioVentures has 20 tracked investments.
- What sectors does 7G BioVentures focus on?
- 7G BioVentures focuses on Biotech, Healthtech.
- Where is 7G BioVentures located?
- 7G BioVentures is headquartered in Burlingame, US.
- Who does 7G BioVentures co-invest with?
- 7G BioVentures most often shares deals with Beresford Ventures, Sanofi Ventures, Anzu Partners, among 13 tracked co-investors.
Images
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.